SCHEDULE M-II
Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Cosmetics
Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Cosmetics
Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Homoeopathic Medicines
GOOD MANUFACTURING PRACTICES FOR ACTIVE PHARMACEUTIAL INGREDIENTS-API (BULK DRUGS)
SCHEDULE M – GMP – PART 7 (API-BULK DRUGS) Read More »
GOOD MANUFACTURING PRACTICES FOR METERED-DOSE-INHALERS (MDI)
SCHEDULE M – GMP – PART 6 (METERED-DOSE-INHALERS) Read More »
GOOD MANUFACTURING PRACTICES FOR TOPICAL PRODUCTS i.e. EXTERNAL PREPARATIONS (CREAMS, OINTMENTS, PASTES, MULSIONS, LOTIONS, SOLUTIONS, DUSTING POWDERS AND IDENTICAL PRODUCTS)
SCHEDULE M – GMP – PART 5 (TOPICAL PRODUCTS) Read More »
GOOD MANUFACTURING PRACTICES FOR ORAL LIQUIDS (SYRUPS, ELIXIRS, EMULSIONS AND SUSPENSIONS)
SCHEDULE M – GMP – PART 4 (ORAL LIQUIDS) Read More »
GOOD MANUFACTURING PRACTICES FOR STERILE PRODUCTS, PARENTERAL PREPARATIONS (SMALL VOLUME INJECTABLES AND LARGE VOLUME PARENTERALS) AND STERILE OPHTHALMIC PREPARATIONS.
SCHEDULE M – GMP – PART 3 (PARENTERAL PREPARATIONS) Read More »
GOOD MANUFACTURING PRACTICES FOR ORAL SOLID DOSAGE FORMS (TABLETS AND CAPSULES)
SCHEDULE M – GMP – PART 2 (OSD) Read More »
Data integrity is the fundamental principle of ensuring that data is accurate, reliable, and consistent throughout its entire lifecycle.
Data Integrity – ALCOA+ Read More »
Corrective and preventative action (CAPA) in pharma refers to the process of identifying, investigating, and addressing any issues or deviations that may have occurred during the production of pharmaceutical products.
What is CAPA – Corrective and preventative action Read More »